Current Psychiatry Reports

, Volume 14, Issue 4, pp 370–375 | Cite as

Feasible Evidence-Based Strategies to Manage Depression in Primary Care

  • Benji T. Kurian
  • Bruce Grannemann
  • Madhukar H. Trivedi
Psychiatry in Primary Care (BN Gaynes, Section Editor)


According to the World Health Organization, major depressive disorder (MDD) is a leading cause of disability-adjusted life years worldwide. However, recent evidence suggests depression remains undertreated in primary care settings. Measurement-based care (MBC) is an evidence-based strategy that can feasibly assist primary care physicians in managing patients with MDD. Utilizing health information technology tools, such as computer decision support software, can improve adherence to evidence-based treatment guidelines and MBC at the point of care.


Depression Primary care Evidence-based guidelines Measurement-based care Clinical assessments Clinical decision support systems Electronic health records Barriers to implementation Residual symptoms Patient-centered outcomes Suicidal ideation Suicide-related behavior Medication side effect Medication adherence Treatment Remission Computer decision support systems 



Dr Kurian has received research funding from National Institute of Mental Health (NIMH), Feinstein Institute for Medical Research, and Agency for Healthcare Research and Quality (AHRQ), and research support from Targacept, Pfizer, Johnson & Johnson, Evotec, Rexahn, Naurex, and Forest Pharmaceuticals.

Mr Grannemann reported no potential conflicts of interest relevant to this article.

Madhukar H. Trivedi is or has been an advisor/consultant to, or on the Speakers’ Bureaus for: Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Rexahn Pharmaceuticals, Sepracor, SHIRE Development, Sierra, SK Life and Science, Takeda, Tal Medical/Puretech Venture, Transcept, VantagePoint, and Wyeth-Ayerst Laboratories. In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), Corcept Therapeutics, Inc., Cyberonics, Inc., Merck, National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals (Epix), Solvay Pharmaceuticals, Inc., Targacept, and Valient.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105.PubMedCrossRefGoogle Scholar
  2. 2.
    Murray CJ, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996;274:740–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Karasz A, Dowrick C, Byng R, et al. What we talk about when we talk about depression: doctor-patient conversations and treatment decision outcomes. Br J Gen Pract. 2012;62:55–63.CrossRefGoogle Scholar
  4. 4.
    Trivedi MH, Claassen CA, Grannemann BD, et al. Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationale. Contemp Clin Trial. 2007;28:192–212.CrossRefGoogle Scholar
  5. 5.
    Trivedi MH, Kern JK, Grannemann BD, Altshuler KZ, Sunderajan P. A computerized clinical decision support system as a means of implementing depression guidelines. Psychiatr Serv. 2004;55:879–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry. 2001;62(Suppl 26):5–9.PubMedGoogle Scholar
  7. 7.
    Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97–108.PubMedCrossRefGoogle Scholar
  8. 8.
    Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145:39–48.PubMedCrossRefGoogle Scholar
  9. 9.
    Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75:57–66.PubMedCrossRefGoogle Scholar
  11. 11.
    Biggs MM, Shores-Wilson K, Rush AJ, et al. A comparison of alternative assessments of depressive symptom severity: a pilot study. Psychiatry Res. 2000;95:55–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology. 2007;32:2479–89.PubMedCrossRefGoogle Scholar
  13. 13.
    Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Morris DW, Trivedi MH. Measurement-based care for unipolar depression. Curr Psychiatry Rep. 2011;13:446–58. This is an updated review of the principles and guidelines behind the use of MBC for depression, and includes patient self-report data for suicidal risk and associated symptoms.PubMedCrossRefGoogle Scholar
  15. 15.
    Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88 Suppl 2:S61–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493–501.PubMedCrossRefGoogle Scholar
  17. 17.
    Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Arnau RC, Meagher MW, Norris MP, Bramson R. Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients. Health Psychol. 2001;20:112–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Riskind JH, Beck AT, Brown G, Steer RA. Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton scales. J Nerv Ment Dis. 1987;175:474–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213.PubMedCrossRefGoogle Scholar
  23. 23.
    Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011;72:757–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. J Clin Psychiatry. 2011;72:765–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343–81.PubMedGoogle Scholar
  27. 27.
    Kwon A, Bungay KM, Pei Y, et al. Antidepressant use: concordance between self-report and claims records. Med Care. 2003;41:368–74.PubMedGoogle Scholar
  28. 28.
    Committee on Quality of Health Care in America IoM. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: Institute of Medicine; 2001.Google Scholar
  29. 29.
    Kanouse DE, Winkler JD, Kosecoff J, et al. Changing medical practice through technology assessment: an evaluation of the NIH Consensus Development Program. Santa Monica, CA: RAND; 1989.Google Scholar
  30. 30.
    Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989;321:1306–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Woolf SH. Practice guidelines: a new reality in medicine. III. Impact on patient care. Arch Int Med. 1993;153:2646–55.CrossRefGoogle Scholar
  32. 32.
    Berlowitz DR, Ash AS, Glickman M, et al. Developing a quality measure for clinical inertia in diabetes care. Health Serv Res. 2005;40:1836–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Int Med. 2001;135:825–34.PubMedGoogle Scholar
  34. 34.
    Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317:465–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458–65.PubMedCrossRefGoogle Scholar
  36. 36.
    • Kurian BT, Trivedi MH, Grannemann BD, Claassen CA, Daly EJ, Sunderajan P. A computerized decision support system for depression in primary care. J Clin Psychiatry. 2009;11:140–6. This is a relevant study that assessed the impact of a computer decision support software for treating depression in primary care.Google Scholar
  37. 37.
    Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA. 2002;288:2469–75.PubMedCrossRefGoogle Scholar
  38. 38.
    Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA. 2005;293:1223–38.PubMedCrossRefGoogle Scholar
  39. 39.
    • Haynes RB, Wilczynski NL. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: methods of a decision-maker-researcher partnership systematic review. Implement Sci. 2010;5:12. An updated review of their comprehensive 2005 review of implementing CDSSs and barriers associated with implementation.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Benji T. Kurian
    • 1
  • Bruce Grannemann
    • 1
  • Madhukar H. Trivedi
    • 1
  1. 1.Department of PsychiatryUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations